Michael Yee
Stock Analyst at UBS
Total Price Targets
42
Stocks Covered
22
Sectors
Healthcare
Most Recent
Mar 6, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Michael Yee
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $70.00 | $58.22 | +20.2% | 1 | Mar 6, 2026 |
| ACLX | Arcellx, Inc. | $115.00 | $115.07 | -0.1% | 2 | Feb 24, 2026 |
| BEAM | Beam Therapeutics Inc. | $28.00 | $31.02 | -9.8% | 1 | Jan 7, 2026 |
| KOD | Kodiak Sciences Inc. | $50.00 | $44.09 | +13.4% | 2 | Jan 7, 2026 |
| ANAB | AnaptysBio, Inc. | $70.00 | $66.67 | +5.0% | 1 | Jan 7, 2026 |
| MBX | MBX Biosciences, Inc. Common Stock | $60.00 | $30.09 | +99.4% | 1 | Jan 7, 2026 |
| NUVB | Nuvation Bio Inc. | $10.00 | $4.50 | +122.5% | 2 | Jan 7, 2026 |
| OLMA | Olema Pharmaceuticals, Inc. | $45.00 | $14.47 | +210.9% | 2 | Jan 7, 2026 |
| ORKA | Oruka Therapeutics, Inc. | $50.00 | $62.83 | -20.4% | 2 | Jan 7, 2026 |
| SABS | SAB Biotherapeutics, Inc. | $7.00 | $3.52 | +99.1% | 1 | Jan 7, 2026 |
| SDGR | Schrödinger, Inc. | $18.00 | $12.37 | +45.6% | 1 | Jan 7, 2026 |
| SRRK | Scholar Rock Holding Corporation | $60.00 | $46.75 | +28.3% | 1 | Jan 7, 2026 |
| COGT | Cogent Biosciences, Inc. | $60.00 | $36.84 | +62.9% | 1 | Jan 7, 2026 |
| DNLI | Denali Therapeutics Inc. | $25.00 | $18.49 | +35.2% | 2 | Jan 7, 2026 |
| GILD | Gilead Sciences, Inc. | $145.00 | $132.04 | +9.8% | 4 | Jan 7, 2026 |
| LLY | Eli Lilly and Company | $1250.00 | $961.67 | +30.0% | 1 | Jan 6, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $535.00 | $425.06 | +25.9% | 3 | Jan 6, 2026 |
| BIIB | Biogen Inc. | $180.00 | $186.69 | -3.6% | 3 | Dec 9, 2024 |
| AMGN | Amgen Inc. | $380.00 | $328.69 | +15.6% | 2 | Nov 12, 2024 |
| MRNA | Moderna, Inc. | $55.00 | $44.65 | +23.2% | 7 | Oct 14, 2024 |
| IMRX | Immuneering Corporation | $3.00 | $5.39 | -44.3% | 1 | Mar 15, 2024 |
| FATE | Fate Therapeutics, Inc. | $145.00 | $1.55 | +9224.8% | 1 | Oct 25, 2021 |
Recent Activity
- Mar 6, 2026— Set$70.00price target onBMY(Bristol-Myers Squibb Company)
- Feb 24, 2026— Set$115.00price target onACLX(Arcellx, Inc.)
- Jan 7, 2026— Set$60.00price target onCOGT(Cogent Biosciences, Inc.)
- Jan 7, 2026— Set$70.00price target onANAB(AnaptysBio, Inc.)
- Jan 7, 2026— Set$28.00price target onBEAM(Beam Therapeutics Inc.)
- Jan 7, 2026— Set$100.00price target onACLX(Arcellx, Inc.)
- Jan 7, 2026— Set$25.00price target onDNLI(Denali Therapeutics Inc.)
- Jan 7, 2026— Set$145.00price target onGILD(Gilead Sciences, Inc.)
- Jan 7, 2026— Set$50.00price target onKOD(Kodiak Sciences Inc.)
- Jan 7, 2026— Set$60.00price target onMBX(MBX Biosciences, Inc. Common Stock)
- Jan 7, 2026— Set$10.00price target onNUVB(Nuvation Bio Inc.)
- Jan 7, 2026— Set$45.00price target onOLMA(Olema Pharmaceuticals, Inc.)
- Jan 7, 2026— Set$50.00price target onORKA(Oruka Therapeutics, Inc.)
- Jan 7, 2026— Set$7.00price target onSABS(SAB Biotherapeutics, Inc.)
- Jan 7, 2026— Set$18.00price target onSDGR(Schrödinger, Inc.)
- Jan 7, 2026— Set$60.00price target onSRRK(Scholar Rock Holding Corporation)
- Jan 6, 2026— Set$535.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Jan 6, 2026— Set$1250.00price target onLLY(Eli Lilly and Company)
- Dec 10, 2025— Set$43.00price target onOLMA(Olema Pharmaceuticals, Inc.)
- Dec 9, 2024— Set$20.00price target onKOD(Kodiak Sciences Inc.)
Frequently Asked Questions
Who is Michael Yee?
Michael Yee is a stock analyst at UBS covering 22 stocks primarily in Healthcare. They have issued 42 price targets since Oct 25, 2021.
What stocks does Michael Yee cover?
Michael Yee currently covers 22 stocks, including MRNA, GILD, VRTX, BIIB, ACLX.
What is Michael Yee's latest price target?
Michael Yee's most recent price target was $70.00 on BMY (Bristol-Myers Squibb Company), set on Mar 6, 2026.
What is Michael Yee's highest price target?
Michael Yee's highest issued price target is $1250.00 on LLY, set on Jan 6, 2026.
More Analysts at UBS
Coverage based on publicly published price targets. Not investment advice.